Navigation Links
Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
Date:1/23/2013

THOUSAND OAKS, Calif., Jan. 23, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2012. Key results include:

  • For the full year, total revenues increased 11 percent to $17,265 million, with 9 percent product sales growth driven by strong performance across the portfolio. Adjusted EPS grew 22 percent to $6.51 due to 15 percent adjusted operating income growth and lower shares outstanding. 
  • For the fourth quarter, total revenues increased 11 percent to $4,421 million, with product sales growing at the same rate. Adjusted EPS grew 16 percent to $1.40 due to 11 percent adjusted operating income growth and lower shares outstanding. 
  • GAAP EPS were $1.01 in the fourth quarter compared to $1.08 a year ago, and were $5.52 for the full year compared to $4.04 in 2011. Full year 2011 was negatively impacted by a previously disclosed charge for a legal settlement reserve.
  • Free cash flow for the full year was $5.2 billion compared to $4.5 billion in 2011.
  • The Company announced that it has initiated Phase 3 studies for AMG 145 in subjects with high levels of low-density lipoprotein (LDL) cholesterol. 
  • "We achieved strong operating performance in 2012 as we delivered for patients and created value for shareholders," said Robert A. Bradway, chairman and chief executive officer at Amgen.  "We enter 2013 with good momentum, a broad late-stage pipeline and a continued focus on building our business internationally."Year-over-YearYear-over-Year$Millions, except EPS and percentagesQ4 '12Q4 '11YOY ΔFY '12FY '11YOY ΔTotal Revenues$4,421$3,97311%$17,265$15,58211%Adjusted Net Income1,0881,0395%5,1194,8585%Adjusted EPS1.401.2116%6.515.3322%GAAP Net Income788934(16%)4,3453,68318%GAAP EPS$1.01$1.08(6%)$5.52$4.0437%References in this release to
    '/>"/>

    SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
    2. MDHI Receives Term Sheet for Working Capital and Acquisition Financing -- Company Hits Profitability on Recurring Revenues
    3. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
    4. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
    5. AMILPAR - Revenues Grow 18% and EBITDA Increases 19% in 1H12
    6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
    7. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
    8. CitiusTech Announces H1 2012 Results - 65% Growth in Half Year Revenues
    9. Herborium Group Reports Record 6 Month Revenues
    10. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
    11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
    (Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
    Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
    (Date:7/10/2014)... more likely to be diagnosed with more aggressive ... for shorter times than prostate cancer patients who ... , The negative outcomes may be the result ... mentally ill, depression,s impact on biological cancer processes, ... general health and disinterest in receiving more effective ...
    (Date:7/10/2014)... Men who experience hot flashes are unlikely to talk ... their silent suffering if they are willing to ... Baylor University case study., After seven weeks of hypnotic ... flashes following prostate cancer surgery showed a drastic decrease ... improvement in sleep quality, according to the study., The ...
    (Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
    (Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
    (Date:7/9/2014)... Cancer Center paint a relatively optimistic picture of women,s ... have spread to the chest wall or skin, but ... skin, regardless of size and whether they have involved ... and called "locally advanced" tumors, suggesting that they are ... survival. Locally advanced breast cancers of this and other ...
    Breaking Medicine News(10 mins):Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Urban Aboriginal people face unique health challenges 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3
    ... , , , ... a contribution of up to $81.4 million to the Healthy Families Program ... children at risk of losing coverage due to the state,s fiscal crisis. ... be used to cover children ages 0-5 through June 2010. , ...
    ... studies find types of hormones used raise or lower ... The composition of a woman,s contraceptive pill influences her ... lung, European researchers say. , Scientists have long known ... and progestogen, increase the likelihood of deep vein thrombosis ...
    ... , , EDINA, Minn., Aug. 13 ... best interest of patients as a key focal point. We do ... and credit card fraud recently announced in the news. The MCA ... protect the public interest in this unfortunate situation. , ...
    ... , , , ... regarding changes to Mississippi Medicaid benefits for speech therapy services, The ... Mississippi Division of Medicaid on the new Medicaid claiming policy for ... for speech therapy services provided by school providers, which are in ...
    ... , , DEERFIELD, Ill., Aug. ... supplier of protective packaging products and specialty packaging solutions, today ... , For the second quarter of 2009, ... of 28.8% versus net sales of $275.2 million in the ...
    ... SANTA FE, N.M., Aug. 13 The New Mexico ... new alliance to assist school districts with Medicaid claiming. This program ... will be administered by Accelify. , , "We ... Executive Director. "NMSBA is focused on bringing value-added programs to New ...
    Cached Medicine News:Health News:First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Program's Viability 2Health News:Some Birth Control Pills Safer Than Others 2Health News:Some Birth Control Pills Safer Than Others 3Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 2Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 3Health News:Pregis Announces Second Quarter 2009 Financial Results 2Health News:Pregis Announces Second Quarter 2009 Financial Results 3Health News:Pregis Announces Second Quarter 2009 Financial Results 4Health News:Pregis Announces Second Quarter 2009 Financial Results 5Health News:Pregis Announces Second Quarter 2009 Financial Results 6Health News:Pregis Announces Second Quarter 2009 Financial Results 7Health News:Pregis Announces Second Quarter 2009 Financial Results 8Health News:Pregis Announces Second Quarter 2009 Financial Results 9Health News:Pregis Announces Second Quarter 2009 Financial Results 10Health News:Pregis Announces Second Quarter 2009 Financial Results 11Health News:Pregis Announces Second Quarter 2009 Financial Results 12Health News:Pregis Announces Second Quarter 2009 Financial Results 13Health News:Pregis Announces Second Quarter 2009 Financial Results 14Health News:Pregis Announces Second Quarter 2009 Financial Results 15Health News:New Mexico School Boards Association and Accelify Announce Alliance to Assist New Mexico Schools 2
    The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
    Steroid eluting pacemaker leads...
    ... Medtronic presents the Streamline family of temporary ... taken the gold standard in temporary pacing ... make them easy to use and less ... 6491 Unipolar Pediatric Temporary Pacing Lead is ...
    Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
    Medicine Products: